PTC Therapeutics
PTCT
203 hedge funds and large institutions have $2.93B invested in PTC Therapeutics in 2024 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 71 increasing their positions, 69 reducing their positions, and 26 closing their positions.
126% more call options, than puts
Call options by funds: $5.68M | Put options by funds: $2.51M
20% more capital invested
Capital invested by funds: $2.44B → $2.93B (+$484M)
15% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 26
2% more funds holding
Funds holding: 199 → 203 (+4)
3% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 69
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1.63% less ownership
Funds ownership: 104.08% → 102.46% (-1.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$18.4M |
| 2 |
AC
Armistice Capital
New York
|
+$9.13M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$8.85M |
| 4 |
BlackRock
New York
|
+$7.07M |
| 5 |
Squarepoint
New York
|
+$6.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$37.2M |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$14M |
| 3 |
Morgan Stanley
New York
|
-$12M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$10.6M |
| 5 |
Renaissance Technologies
New York
|
-$9.37M |
PTCT Hedge Fund Activity: Q3 2024 in Review
203 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q3 2024, worth a combined $2.93B — up 20% from $2.44B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new PTCT positions and 26 closed out — a net gain of 4 holders — while 71 added to existing stakes and 69 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $18.4M. The largest seller was Janus Henderson Group, cutting an estimated $37.2M.
- 203 institutional investors held PTC Therapeutics (PTCT) as of Q3 2024, up from 199 in Q2 2024.
- Funds reported $2.93B of PTC Therapeutics stock for Q3 2024, up 20% quarter-over-quarter.
- 30 funds opened new PTC Therapeutics positions in Q3 2024 and 26 closed out, a net change of +4 holders.
- The largest PTC Therapeutics buyer in Q3 2024 was Point72 Asset Management, an estimated $18.4M added.
- The largest PTC Therapeutics seller in Q3 2024 was Janus Henderson Group, an estimated $37.2M sold.
Based on aggregated 13F filings for Q3 2024.